October 17, 2022 4:36pm
The algorithms were in-charge as big part of today’s sector rally was also based on the undervaluation that took place Friday
Pre-open indications: 3 Hits, 1 Miss and 1 Pump/Promote (Biostage (BSTG)
The Biostage (OTCQB: BSTG) Chronicles: the volume pump is working as stock shrills +$0.92 (was +$1.19 with 3,006 shares traded) shouldn’t we thank Beijing, China for the upside share pricing push for the -pending stock reverse and possible offering?
It’s an honor to be considered the “canary in the (sector) coal mine”! I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths …
It’s more than opinion, the facts and truth need to be recognized! Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write
If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed UP +553.96 points (+1.87%), the S&P closed UP +95.08 points (+2.65%) while the Nasdaq closed UP +354.41 points (+3.43%)
Henry’omics:
Indexes rose sharply on Monday as investors weighed key earnings reports after a wild week of trading after all the major equity indexes closed lower Friday on negative internals as all closed at or near their lows of the day.
Today’s moves come as stocks are near the lows of the year. Big moves in both directions in recent weeks have fed a sense of pessimism, though some believed the market was due for a rebound and it did swing-up.
Economic Data Docket: Data on manufacturing in the New York region was weaker than expected, adding fuel to expectations a pivot by the Fed may be on the horizon.
RegMed Investor’s (RMi) Pre-Open: “earnings are the elephant in the room. The market shows signs of strength yet, the sector “seems” weak.” … https://www.regmedinvestors.com/articles/12652
All-time lows:
- Verastem (VSTM) at $0.37
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …
- Monday’s advance/decline line opened positive at 31 up/ 4 down and 0 flat, stayed positive with 29 up/ 6 down and 0 flat at the mid-day, ending with a positive close of 33/2 and 0 acquired.
Pre-open Indications:
- 3 Hit < Intellia Therapeutics (NTLA +$2.20), Fate Therapeutics (FATE +$0.72), CRISPR Therapeutics (CRSP +$2.26)> 1 Miss < Ionis Pharmaceuticals (IONS +$0.16)> 1 Pump/Promote < Biostage (OTCQB: BSTG +$0.92)
Key Metrics:
- Monday - Sector volume was LOW with 7 of the 33-upside having higher than the 3-month average volume with LOW volume of 1 of 2-downside having higher than the 3-month average volume
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday, the IBB was up +2.41% and the XBI was up +3.71%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was down -0.74 points or -2.31% at 31.28
Jumping with share pricing momentum (10 of 33):
- Alnylam Pharmaceuticals (ALNY +$9.56 after Friday’s -$6.23),
- Beam Therapeutics (BEAM +$2.70 after Friday’s -$3.53),
- CRISP Therapeutics (CRSP +$2.26 after Friday’s -$3.99),
- Intellia Therapeutics (NTLA +$2.20 after Friday’s -$2.74),
- Verve Therapeutics (VERV +$1.80 after Friday’s -$2.01),
- Regenxbio (RGNX +$1.36),
- Ultragenyx (RARE +$1.24 after Friday’s -$2.59),
- Chinook Therapeutics (KDNY +$1.16),
- BioLife Solutions (BLFS +$1.11 after Friday’s -$1.20),
- uniQure NV (QURE +$0.97),
Closing down (2 of 2):
- Brainstorm Cell Therapeutics (BCLI -$0.12),
- Homology Medicine (FIXX -$0.06),
Q4 - October
- Monday closed positive with 33 incliner, 2 decliners and 1 flat
The BOTTOM LINE: A welcomed up side as the oversold and undervalued got recognized by electronic trading and algorithms.
I try to keep it simple … and short!
We will be seeing what October brings – Q3 earnings LPS (loss-per-share) season and a whole lot of economic indicators of which we have seen.
Alnylam Pharmaceuticals (ALNY) was the first to declare is Q3 earnings report on Thursday, 10/27 at 8:30 a.m.
October has NEVER been a good month for equities.
DISPOSE Avrobio (AVRO) who experiences news and the stock drops after a de-listing notice while the management DID NOTHING to AVOID this dilemma while president, CEO and director Geoff Mackay carries home a HUGE salary of $754.39 K per year?
· AVRO closed up om Monday +$0.02 to $0.60 which STILL does NOT get close to the $1.00 to continue its Nasdaq listing after a delisting notice.
· Will AVRO have to “commission" a stock reverse to address delisting?
October has 1 neutral, 6 positive and 5 negative closes;
As I continually question, “The real question that should be asked is how many companies are at the end of sentiments … leash?
Start by looking at cell and gene therapy companies trading below cash!”
I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
